Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | PRKACA | P17612 | 2/20 | 0.53 |
| ▸ | PRKX | P51817 | 2/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818830 | 0.88 | ROCK2 (0.59) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14009842 | 0.85 | CDC7 (0.52) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14009844 | 0.83 | ROCK2 (0.64) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14009841 | 0.83 | LMNA (0.53) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14009838 | 0.82 | MLYCD (0.60) | ROCK2ROCK1CYP3A4CYP2D6MMP13 | |
| SCHEMBL14009843 | 0.82 | MAPK1 (0.60) | ROCK2ROCK1PRKACAPRKXGSK3A | |
| SCHEMBL13947591 | 0.81 | MMP13 (0.68) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14009839 | 0.80 | AAK1 (0.47) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27913637 | 0.79 | ROCK2 (0.66) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3810618 | 0.78 | ROCK2 (0.75) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275062-A1 | Chemical Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | ROCK2 3638/4885ROCK1 2695/4885CYP3A4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.